Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Deciphering the Molecular Mechanisms Underlying Low-Grade-Glioma Progression
FY 2024-25
Summary
Dr. Daniel Schramek, Mount Sinai Hospital
Low-grade gliomas (LGGs) are the most common primary malignant brain tumors in young adults, typically diagnosed around the median age of 38 years. Initially, these tumors are relatively benign and can remain asymptomatic for decades. However, nearly all LGGs eventually progress to secondary glioblastoma (GBM), resulting in rapid patient decline and death within a few months. LGGs frequently harbor transforming mutations in IDH1 or IDH2, along with 2-3 other well-characterized genes. Despite this, the specific alterations responsible for progression to fatal GBM remain unclear. Unlike other cancers, LGGs exhibit few driver mutations during progression; instead, they demonstrate significant chromosomal instability and a prevalent and heterogeneous pattern of copy-number alterations (CNAs), suggesting that widespread changes in gene dosage may drive their progression.
In this study, I propose utilizing in-vivo CRISPR screening in robust LGG models to elucidate the molecular mechanisms underlying the transition from LGG to GBM. I will first identify CNAs that are enriched in LGG patients and then perform genetic screens to pinpoint driver genes within these CNAs. By manipulating these genes through CRISPR/Cas9 based deletion or overexpression, I aim to uncover those that promote LGG progression. Subsequently, I will investigate the mechanisms by which these alterations drive tumor evolution to identify potential therapeutic targets for halting the progression from LGG to GBM. The findings from this research will advance our understanding of LGG progression and inform strategies for targeting and preventing the transition to GBM.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
517119
Name
Haider Syed S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Deciphering the Molecular Mechanisms Underlying Low-Grade-Glioma Progression
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Cancer Neuroscience; Copy-Number-Alterations; Crispr/Cas9; Genomics; Idh-Mutant-Glioma; Low-Grade-Glioma; Proteomics
Abstract
Dr. Daniel Schramek, Mount Sinai Hospital
Low-grade gliomas (LGGs) are the most common primary malignant brain tumors in young adults, typically diagnosed around the median age of 38 years. Initially, these tumors are relatively benign and can remain asymptomatic for decades. However, nearly all LGGs eventually progress to secondary glioblastoma (GBM), resulting in rapid patient decline and death within a few months. LGGs frequently harbor transforming mutations in IDH1 or IDH2, along with 2-3 other well-characterized genes. Despite this, the specific alterations responsible for progression to fatal GBM remain unclear. Unlike other cancers, LGGs exhibit few driver mutations during progression; instead, they demonstrate significant chromosomal instability and a prevalent and heterogeneous pattern of copy-number alterations (CNAs), suggesting that widespread changes in gene dosage may drive their progression.
In this study, I propose utilizing in-vivo CRISPR screening in robust LGG models to elucidate the molecular mechanisms underlying the transition from LGG to GBM. I will first identify CNAs that are enriched in LGG patients and then perform genetic screens to pinpoint driver genes within these CNAs. By manipulating these genes through CRISPR/Cas9 based deletion or overexpression, I aim to uncover those that promote LGG progression. Subsequently, I will investigate the mechanisms by which these alterations drive tumor evolution to identify potential therapeutic targets for halting the progression from LGG to GBM. The findings from this research will advance our understanding of LGG progression and inform strategies for targeting and preventing the transition to GBM.
Competitiondate
202410
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Haider, Syed S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~